

**Regulated Information****The Ipsen Group publishes its 2014 Registration Document**

**Paris (France), 31 March 2015** - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its 2014 Registration Document has been filed with the French "Autorité des Marchés Financiers" (AMF) on 27 March 2015 and registered under the number D.15-0221.

The document is available on the company's website: [www.ipsen.com](http://www.ipsen.com) and on the AMF's website: [www.amf-france.org](http://www.amf-france.org). Copies are also available at Ipsen's headquarters – 65 quai Georges Gorse, 92100 Boulogne-Billancourt – France.

The following documents are incorporated into the 2014 Registration Document:

- The Annual Financial Report;
- The Chairman's Report on the preparation and organization of the works of the Board of Directors and internal control procedures and risk management procedures and the corresponding Statutory Auditor's Report;
- The information relating to the fees paid to the Statutory Auditors.

**About Ipsen**

Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen's commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuro-endocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US). In 2014, R&D expenditure totaled close to €187 million, representing about 15% of Group sales. The Group has more than 4,500 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit [www.ipsen.com](http://www.ipsen.com).

**For further information:****Media****Didier Véron**

Senior Vice-Président, Public Affairs  
and Communication  
Tel.: +33 (0)1 58 33 51 16  
Fax: +33 (0)1 58 33 50 58  
E-mail: [didier.veron@ipsen.com](mailto:didier.veron@ipsen.com)

**Brigitte Le Guennec**

Corporate External Communication Manager  
Tel.: +33 (0)1 58 33 51 17  
Fax: +33 (0)1 58 33 50 58  
E-mail : [brigitte.le.guennec@ipsen.com](mailto:brigitte.le.guennec@ipsen.com)

**Financial Community****Stéphane Durant des Aulnois**

Vice-President Investor Relations  
Tel.: +33 (0)1 58 33 60 09  
Fax: +33 (0)1 58 33 50 63  
E-mail: [stephane.durant.des.aulnois@ipsen.com](mailto:stephane.durant.des.aulnois@ipsen.com)

**Thomas Peny-Coblentz, CFA**

Investor Relations Deputy Director  
Tel.: +33 (0)1 58 33 56 36  
Fax: +33 (0)1 58 33 50 63  
E-mail: [thomas.peny-coblentz@ipsen.com](mailto:thomas.peny-coblentz@ipsen.com)